ASCML
CRSP icon

ADKINS SEALE CAPITAL MANAGEMENT LLC’s CRISPR Therapeutics CRSP Stock Holding History

ADKINS SEALE CAPITAL MANAGEMENT LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9K Hold
200
– – 0.01% 200
2026
Q1 		$9.51K Hold
200
– – 0.01% 194
2025
Q4 		$10.5K Buy
+200
New +$12K 0.01% 188

Other funds holding CRSP

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

ADKINS SEALE CAPITAL MANAGEMENT LLC's CRSP Position: Q2 2026 in Review

ADKINS SEALE CAPITAL MANAGEMENT LLC held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 200 shares worth $10.9K. The position accounts for 0.01% of the portfolio, ranked #200.

ADKINS SEALE CAPITAL MANAGEMENT LLC first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • ADKINS SEALE CAPITAL MANAGEMENT LLC held 200 shares of CRISPR Therapeutics worth $10.9K as of Q2 2026.
  • ADKINS SEALE CAPITAL MANAGEMENT LLC left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of ADKINS SEALE CAPITAL MANAGEMENT LLC's portfolio in Q2 2026, its #200 holding.
  • ADKINS SEALE CAPITAL MANAGEMENT LLC first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 219 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on ADKINS SEALE CAPITAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 5 Aug 2026.